# Assessment of Efficacy of KAN-JANG® in Mild COVID-19

> **NCT04847518** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Swedish Herbal Institute AB** · enrollment: 140 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Kan Jang capsules
- **OTHER:** Placebo capsules

## Key facts

- **NCT ID:** NCT04847518
- **Lead sponsor:** Swedish Herbal Institute AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-26
- **Primary completion:** 2022-01
- **Final completion:** 2022-03
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2021-09-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04847518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04847518, "Assessment of Efficacy of KAN-JANG® in Mild COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04847518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*